k Immunotherapy child suffering from cancer receiving infusion of lymphocytes doped with Interleukin2 IL2. IL2 is released naturally by certain key cells of the immune system T lymphocytes after they have been activated by foreign antigens of cancer cells, for instance. IL2 amplifies the proliferation of other cell types, including lymphokineactivated killer LAK cells that attack cancer cells directly. Blood from a cancer victim is purified, the lymphocytes separated then doped with IL2 produced by genetic engineering and cultured in vitro to boost the LAK cell population. The product is then reinjected into the patient. Photographed at Centre Lyon Berard, Lyon, France, 198889. Editorial Stock Photo - Afloimages
Sign up
Login
All images
Immunotherapy: child suffering from cancer receiving infusion of lymphocytes doped with Interleukin-2 (IL-2). IL-2 is released naturally by certain key cells of the immune system (T- lymphocytes) after they have been activated by foreign antigens - of cancer cells, for instance. IL-2 amplifies the proliferation of other cell types, including lymphokine-activated killer (LAK) cells that attack cancer cells directly. Blood from a cancer victim is purified, the lymphocytes separated then doped with IL-2 (produced by genetic engineering) and cultured in vitro to boost the LAK cell population. The product is then re-injected into the patient. Photographed at Centre Lyon Berard, Lyon, France, 1988/89.
ED

Immunotherapy: child suffering from cancer receiving infusion of lymphocytes doped with Interleukin-2 (IL-2). IL-2 is released naturally by certain key cells of the immune system (T- lymphocytes) after they have been activated by foreign antigens - of cancer cells, for instance. IL-2 amplifies the proliferation of other cell types, including lymphokine-activated killer (LAK) cells that attack cancer cells directly. Blood from a cancer victim is purified, the lymphocytes separated then doped with IL-2 (produced by genetic engineering) and cultured in vitro to boost the LAK cell population. The product is then re-injected into the patient. Photographed at Centre Lyon Berard, Lyon, France, 1988/89.

Details

ID
10598400

Collection

License type
Editorial

Photographer

Creation date
18-11-2010

Contact Aflo for all commercial uses.


Keywords
More
Sign in
Member access
Login not found.